Abstract
T cells play the central role in adaptive immunity and deficiencies affecting this key component of the immune system result in the most severe forms of primary immunodeficiency. The classic example within this group of immunodeficiencies is severe combined immunodeficiency (SCID). The infectious complications include a wide spectrum of organisms, but viral infections and opportunistic infections are commonly found in infants with SCID who are not identified by newborn screening (NBS). With NBS for SCID through quantification of T cell receptor excision circles (TRECs), the prognosis associated with this condition has improved considerably, with the vast majority of these infants in the USA found early and often without infectious complications. Conditions of T cell immunity not as severe as SCID are broad, and, in addition to infection, noninfectious complications can develop including lymphoproliferation, inflammation, and autoimmunity, notably inflammatory bowel disease. The relatively poor prognosis of T cell immune deficiencies requires those affected to initiate extensive antimicrobial prophylaxis often combined with immunosuppressive treatments to control inflammatory complications. Definitive therapy often includes hematopoietic cell transplant. There are nearly 90 primary immunodeficiency conditions that are considered predominantly T cell and combined T cell and B cell conditions, not all of which can be covered in the scope of this chapter (Picard et al., J Clin Immunol. 35(8):696–726, 2015). Instead we will focus on severe combined immunodeficiency (SCID) in its various forms as well as highlight specific immune defects that illustrate unique aspects of aberrant T cell immunity and resultant clinical manifestations.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for primary immunodeficiency 2015. J Clin Immunol. 2015;35(8):696–726.
Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729–38.
Klinkenberg D, Blohm M, Hoehne M, Mas Marques A, Malecki M, Schildgen V, et al. Risk of rotavirus vaccination for children with SCID. Pediatr Infect Dis J. 2015;34(1):114–5.
Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplant outcomes for severe combined immunodeficiency, 2000–2009. N Engl J Med. 2014;371(5):434–46.
Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Puck JM, Logan BR, et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014;133(4):1092–8.
Müller SM, Ege M, Pottharst A, Schulz AS, Schwarz K, Friedrich W. Transplacentally acquired maternal T lymphocytes in severe combined immunodeficiency: a study of 121 patients. Blood. 2001;98(6):1847–51.
Kovanen PE, Leonard WJ. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev. 2004;202:67–83.
Schatz DG, Ji Y. Recombination centres and the orchestration of V(D)J recombination. Nat Rev Immunol. 2011;11(4):251–63.
Hirschhorn R, Martiniuk F, Rosen FS. Adenosine deaminase activity in normal tissues and tissues from a child with severe combined immunodeficiency and adenosine deaminase deficiency. Clin Immunol Immunopathol. 1978;9(3):287–92.
Schrader WP, Stacy AR. Purification and subunit structure of adenosine deaminase from human kidney. J Biol Chem. 1977;252(18):6409–15.
Benveniste P, Cohen A. p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc Natl Acad Sci U S A. 1995;92(18):8373–7.
Cowan MJ, Gennery AR. Radiation-sensitive severe combined immunodeficiency: the arguments for and against conditioning before hematopoietic cell transplantation-what to do? J Allergy Clin Immunol. 2015;136(5):1178–85.
Ma Y, Pannicke U, Schwarz K, Lieber MR. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V (D) J recombination. Cell. 2002;108(6):781–94.
Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL-7R expression in T(2)B(1)NK(1) severe combined immunodeficiency. Nat Genet. 1998;20(4):394–7.
Buckley RH, Schiff RI, Schiff SE, Markert ML, Williams LW, Harville TO, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr. 1997;130:378–87.
Stephan JL, Vlekova V, Le Deist F, Blanche S, Donadieu J, DeSaint-Basile G, et al. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J Pediatr. 1993;123(4):564–71.
Omenn GS. Familial reticuloendotheliosis with eosinophilia. N Engl J Med. 1965;273:427–32.
Chan SK, Gelfand EW. Primary immunodeficiency masquerading as allergic disease. Immunol Allergy Clin N Am. 2015;35(4):767–78.
Geier CB, Piller A, Linder A, Sauerwein KM, Eibl MM, Wolf HM. Leaky RAG deficiency in adult patients with impaired antibody production against bacterial polysaccharide antigens. PLoS One. 2015;10(7):1–16.
Kesserwan C, Sokolic R, Cowen EW, Garabedian E, Heselmeyer-Haddad K, Lee CC, Pittaluga S, Ortiz C, Baird K, Lopez-Terrada D, Bridge J. Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase–deficient severe combined immune deficiency. J Allergy Clin Immunol. 2012;129(3):762–9.
Albuquerque W, Gaspar HB. Bilateral sensorineural deafness in adenosine deaminase-deficient severe combined immunodeficiency. J Pediatr. 2004;144(2):278–80.
Shovlin CL, Hughes JM, Simmonds HA, Fairbanks L, Deacock S, Lechler R, et al. Adult presentation of adenosine deaminase deficiency. Lancet. 1993;341(8858):1471.
Ozsahin H, Arredondo-Vega FX, Santisteban I, Fuhrer H, Tuchschmid P, Jochum W, et al. Adenosine deaminase deficiency in adults. Blood. 1997;89(8):2849–55.
Li L, Moshous D, Zhou Y, Wang J, Xie G, Salido E, et al. A founder mutation in Artemis, an SNM1-like protein, causes SCID in Athabascan-speaking Native Americans. J Immunol. 2002;168(12):6323–9.
Mazzucchelli RI, Riva A, Durum SK. The human IL-7 receptor gene: deletions, polymorphisms and mutations. Semin Immunol. 2012;24(3):225–30.
Kwan A, Puck JM. History and current status of newborn screening for severe combined immunodeficiency. Semin Perinatol. 2015;39(3):194–205. WB Saunders
Speckmann C, Pannicke U, Wiech E, Schwarz K, Fisch P, Friedrich W, Niehues T, Gilmour K, Buiting K, Schlesier M, Eibel H. Clinical and immunologic consequences of a somatic reversion in a patient with X-linked severe combined immunodeficiency. Blood. 2008;112(10):4090–7.
Cicalese MP, Aiuti A. Clinical applications of gene therapy for primary immunodeficiencies. Hum Gene Ther. 2015;26(4):210–9.
Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5):447–58.
Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine. 2003;82(6):373–84.
van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67(1):2–17.
Notarangelo LD, Duse MA, Ugazio AG. Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev. 1991;3(2):101–21.
Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, Resnick I, Fasth A, Baer M, Gomez L, Sanders EA. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr. 1997;131(1):47–54.
Harry W. Primary antibody deficiencies. Clin Immunol Princ Pract. 2012;26:421.
Hayward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A, et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol. 1997;158(2):977–83.
Cunningham CK, Bonville CA, Ochs HD, Seyama K, John PA, Rotbart HA, Weiner LB. Enteroviral meningoencephalitis as a complication of X-linked hyper IgM syndrome. J Pediatr. 1999;134(5):584–8.
Kwan SP, Lehner T, Hagemann T, Lu B, Blaese M, Ochs H, et al. Localization of the gene for the Wiskott-Aldrich syndrome between two flanking markers, TIMP and DXS255, on Xp11. 22–Xp11. 3. Genomics. 1991;10(1):29–33.
Beel K, Vandenberghe P. G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. Haematologica. 2009;94(10):1449–52.
Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2006;117(4):725–38.
Fuller CL, Braciale VL, Samelson LE. All roads lead to actin: the intimate relationship between TCR signaling and the cytoskeleton. Immunol Rev. 2003;191(1):220–36.
Zhu Q, Watanabe C, Liu T, Hollenbaugh D, Blaese RM, Kanner SB, Aruffo A, Ochs HD. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood. 1997;90(7):2680–9.
Orange JS. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol. 2008;8(9):713–25.
Ochs HD, Filipovich AH, Veys P, Cowan MJ, Kapoor N. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transpl. 2009;15(1):84–90.
Molina IJ, Sancho J, Terhorst C, Rosen FS, Remold-O’Donnell E. T cells of patients with the Wiskott-Aldrich syndrome have a restricted defect in proliferative responses. J Immunol. 1993;151(8):4383–90.
Naumova AK, Plenge RM, Bird LM, Leppert M, Morgan K, Willard HF, Sapienza C. Heritability of X chromosome-inactivation phenotype in a large family. Am J Hum Genet. 1996;58(6):1111.
Moratto D, Giliani S, Bonfim C, Mazzolari E, Fischer A, Ochs HD, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980–2009: an international collaborative study. Blood. 2011;118(6):1675–84.
Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, et al. Gene therapy for Wiskott-Aldrich syndrome – long-term efficacy and genotoxicity. Sci Transl Med. 2014;6(227):227–33.
Ouederni M, Vincent QB, Frange P, Touzot F, Scerra S, Bejaoui M, et al. Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients. Blood. 2011;118(19):5108–18.
Shrestha D, Szöllősi J, Jenei A. Bare lymphocyte syndrome: an opportunity to discover our immune system. Immunol Lett. 2012;141(2):147–57.
Hanna S, Etzioni A. MHC class I and II deficiencies. J Allergy Clin Immunol. 2014;134(2):269–75.
Picard C, Fischer A. Hematopoietic stem cell transplantation and other management strategies for MHC class II deficiency. Immunol Allergy Clin N Am. 2010;30(2):173–8.
Siepermann M, Gudowius S, Beltz K, Strier U, Feyen O, Troeger A, et al. MHC class II deficiency cured by unrelated mismatched umbilical cord blood transplantation: case report and review of 68 cases in the literature. Pediatr Transplant. 2011;15(4):E80–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Dorsey, M.J., Cowan, M.J. (2018). T Cell Defects. In: Segal, B. (eds) Management of Infections in the Immunocompromised Host. Springer, Cham. https://doi.org/10.1007/978-3-319-77674-3_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-77674-3_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-77672-9
Online ISBN: 978-3-319-77674-3
eBook Packages: MedicineMedicine (R0)